Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 19/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159630 | 1.00 | GSK3B (0.54) | GSK3BDYRK1AABL1 | |
| SCHEMBL20227778 | 0.82 | ABL1 (0.59) | GSK3BDYRK1AABL1 | |
| SCHEMBL30636341 | 0.81 | GSK3B (0.60) | GSK3BDYRK1AABL1 | |
| SCHEMBL28166698 | 0.81 | GSK3B (0.60) | GSK3BDYRK1AABL1 | |
| SCHEMBL479056 | 0.81 | NAMPT (0.43) | GSK3BDYRK1A | |
| SCHEMBL1258539 | 0.80 | ATR (0.47) | GSK3BDYRK1A | |
| SCHEMBL2924493 | 0.80 | CA12 (0.48) | — | |
| SCHEMBL30381612 | 0.80 | GSK3B (0.54) | GSK3BDYRK1AABL1 | |
| SCHEMBL25303717 | 0.80 | GSK3B (0.54) | GSK3BDYRK1AABL1 | |
| SCHEMBL10288086 | 0.79 | GSK3B (0.54) | GSK3BDYRK1AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| CN-115427035-A | ENL/AF9YEATS inhibitors | 洛克菲勒大学 | 2022-12-02 | — | — | CN | disclosed |
| EP-4076440-A1 | INHIBITORS OF ENL/AF9 YEATS | The Rockefeller University (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | MLLT3, YEATS2, MLLT1 | GSK3B 3834/4885DYRK1A 1585/4885ABL1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.